DK0762888T3 - Copolymer-1 forbedringer i præparater af copolymerer - Google Patents

Copolymer-1 forbedringer i præparater af copolymerer

Info

Publication number
DK0762888T3
DK0762888T3 DK95920632T DK95920632T DK0762888T3 DK 0762888 T3 DK0762888 T3 DK 0762888T3 DK 95920632 T DK95920632 T DK 95920632T DK 95920632 T DK95920632 T DK 95920632T DK 0762888 T3 DK0762888 T3 DK 0762888T3
Authority
DK
Denmark
Prior art keywords
copolymer
preparations
kilodaltons
species
molecular weight
Prior art date
Application number
DK95920632T
Other languages
Danish (da)
English (en)
Inventor
Eliezer Konfino
Michael Sela
Dvora Teitelbaum
Ruth Arnon
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26939072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0762888(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK0762888T3 publication Critical patent/DK0762888T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polyamides (AREA)
DK95920632T 1994-05-24 1995-05-23 Copolymer-1 forbedringer i præparater af copolymerer DK0762888T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24803794A 1994-05-24 1994-05-24
US34424894A 1994-11-23 1994-11-23
PCT/US1995/006551 WO1995031990A1 (fr) 1994-05-24 1995-05-23 Ameliorations apportees a des compositions de copolymeres contenant du copolymere-1

Publications (1)

Publication Number Publication Date
DK0762888T3 true DK0762888T3 (da) 2002-05-27

Family

ID=26939072

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95920632T DK0762888T3 (da) 1994-05-24 1995-05-23 Copolymer-1 forbedringer i præparater af copolymerer

Country Status (31)

Country Link
US (11) US5800808A (fr)
EP (1) EP0762888B1 (fr)
JP (2) JPH10500955A (fr)
KR (1) KR100403750B1 (fr)
CN (2) CN1310673C (fr)
AT (1) ATE212857T1 (fr)
AU (1) AU2602195A (fr)
BR (2) BR9507758A (fr)
CA (1) CA2191088C (fr)
CZ (1) CZ292247B6 (fr)
DE (2) DE69525340T2 (fr)
DK (1) DK0762888T3 (fr)
EE (1) EE03423B1 (fr)
ES (1) ES2172586T3 (fr)
FI (1) FI120236B (fr)
GE (1) GEP20002205B (fr)
HK (1) HK1008657A1 (fr)
HU (1) HU223473B1 (fr)
IL (2) IL113812A (fr)
LU (1) LU90987I2 (fr)
MD (1) MD1443G2 (fr)
NL (1) NL300096I2 (fr)
NO (1) NO324528B1 (fr)
NZ (1) NZ287335A (fr)
PL (1) PL181026B1 (fr)
PT (1) PT762888E (fr)
SI (1) SI0762888T1 (fr)
SK (1) SK283699B6 (fr)
TJ (1) TJ392B (fr)
UA (1) UA62908C2 (fr)
WO (1) WO1995031990A1 (fr)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6036957A (en) * 1990-03-30 2000-03-14 Autoimmune, Inc. Suppression of T-cell proliferation using peptide fragments of myelin basic protein
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US7090982B2 (en) 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
EP1054880A1 (fr) * 1998-02-13 2000-11-29 Autoimmune, Inc. Traitement de la sclerose en plaques en utilisant le cop-1 et les cytokines de renforcement des th2
AU766498B2 (en) 1998-07-23 2003-10-16 President And Fellows Of Harvard College, The Synthetic peptides and methods of use for autoimmune disease therapies
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) * 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
ES2327301T3 (es) 1998-09-25 2009-10-27 Yeda Research And Development Co., Ltd. Polipeptidos relacionados con el copolimero 1 para su uso como marcadores de pesos moleculares y para uso terapeutico.
AU6281599A (en) * 1998-10-02 2000-04-26 Yeda Research And Development Co. Ltd. Alternate day administration of copolymer 1 for treating autoimmune diseases
US7083777B1 (en) 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
JP4328050B2 (ja) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
US7022663B2 (en) * 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
MXPA02008023A (es) * 2000-02-18 2005-06-30 Yeda Res & Dev Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
IL153236A0 (en) * 2000-06-05 2003-07-06 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
ATE314860T1 (de) * 2000-06-07 2006-02-15 Yeda Res & Dev Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaet
IL148202A0 (en) * 2000-06-20 2002-09-12 Caprion Pharmaceuticals Inc Copolymers and methods of treating prion-related diseases
WO2002076503A1 (fr) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Traitement de maladies du systeme nerveux central au moyen d'anticorps diriges contre l'acetate de glatiramere
IL137460A0 (en) 2000-07-24 2001-07-24 Yeda Res & Dev Identifying antigen clusters for monitoring a global state of an immune system
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
GB2369896A (en) 2000-12-06 2002-06-12 Marconi Comm Ltd Tunable optical filter actuator
KR100442122B1 (ko) * 2001-07-31 2004-07-30 한국전기연구원 영구 자석을 이용한 브러시리스 발전기
ATE475883T1 (de) * 2001-12-04 2010-08-15 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
HU228207B1 (hu) * 2001-12-06 2013-01-28 Yeda Res & Dev Vakcina és eljárás mozgatóneuron-betegségek kezelésére
US20060057107A1 (en) * 2001-12-21 2006-03-16 Shaked Ze Ev Combination treatment for multiple sclerosis
CA2512735C (fr) 2003-01-07 2016-03-08 Yeda Research And Development Co. Ltd. Vaccin sous forme de gouttes ophtalmiques contenant un copolymere-1 destine a l'immunisation therapeutique
PT1592384E (pt) * 2003-01-21 2013-01-28 Yeda Res & Dev Cop-1 para o tratamento de doenças inflamatórias do intestino
CA2518079A1 (fr) * 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Traitement combine a base d'acetate de glatiramer et d'alphacalcidol, destine au traitement de la sclerose en plaques
EP1638581A2 (fr) 2003-03-31 2006-03-29 The Brigham And Women's Hospital, Inc. Immunomodulateurs zwitterioniques destines au traitement de l'asthme et des allergies
WO2005056574A2 (fr) 2003-12-09 2005-06-23 Yeda Research And Development Co. Ltd. Methode et vaccin comprenant le copolymere 1 pour le traitement de troubles psychiatriques
JP2007509981A (ja) * 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子
EP2301569B1 (fr) 2003-11-12 2018-05-02 Yeda Research and Development Co. Ltd. Vaccin et procédé pour le traitement des maladies neurodégénératives
EP1725099A4 (fr) * 2004-02-02 2009-08-19 Mixture Sciences Inc Melanges de peptides a activite immunomodulatrice
CA2558655A1 (fr) * 2004-03-01 2005-09-15 Kai W. Wucherpfennig Methodes et compositions pour traiter des maladies auto-immunes
US20070244056A1 (en) * 2004-03-03 2007-10-18 Liat Hayardeny Combination Therapy With Glatiramer Acetate and Riluzole
US20050260770A1 (en) * 2004-04-01 2005-11-24 Cohen Irun R Antigen array and diagnostic uses thereof
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
ES2560448T3 (es) 2004-05-07 2016-02-19 Ares Trading S.A. Procedimientos de tratamiento de enfermedades con copolímeros aleatorios
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
AU2005259991B2 (en) 2004-06-25 2011-05-26 Id Biomedical Corporation Of Quebec Compositions and methods for treating neurological disorders
WO2006029411A2 (fr) * 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Melanges de polypeptides, compositions les contenant et leurs procedes de preparation et d'utilisation
DE602005018800D1 (de) * 2004-09-09 2010-02-25 Teva Pharma Verfahren zur herstellung von polypeptidmischungen unter anwendung von aufgereinigter bromwasserstoffsäure
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
CN101044188B (zh) * 2004-10-29 2010-08-04 桑多斯股份公司 制备格拉太咪尔的方法
WO2006057003A2 (fr) * 2004-11-29 2006-06-01 Yeda Research And Development Co. Ltd. Induction de neurogenese et therapie par cellules souches en combinaison avec le copolymere 1
NZ556156A (en) * 2005-02-02 2010-03-26 Teva Pharma Process for producing acetate salts of polypeptides using hydrogenolysis
PT1848415E (pt) * 2005-02-17 2013-06-27 Teva Pharma Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
US20060240463A1 (en) * 2005-04-25 2006-10-26 Rappaport Family Institute For Research In The Medical Sciences Markers associated with the therapeutic efficacy of glatiramer acetate
WO2007081975A2 (fr) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Méthode de traitement de la sclérose en plaques
US8206726B2 (en) 2006-02-06 2012-06-26 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
WO2007120834A2 (fr) 2006-04-13 2007-10-25 Peptimmune, Inc. Procédés de conception et de synthèse de compositions de polymères à séquence dirigée par expansion dirigée de la perméabilité épitopique
ES2565035T3 (es) 2006-04-28 2016-03-30 Momenta Pharmaceuticals, Inc. Métodos para evaluar mezclas de péptidos
KR100831796B1 (ko) * 2006-05-29 2008-05-28 엘지전자 주식회사 타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
CA2656463C (fr) 2006-06-28 2015-12-01 Yeda Research And Development Co. Ltd. Methode de traitement de la degenerescence maculaire liee a l'age
SI2046817T1 (sl) * 2006-07-05 2010-04-30 Momenta Pharmaceuticals Inc Izboljšani postopek za pripravo kopolimera-1
EP2174130A2 (fr) 2007-06-21 2010-04-14 Momenta Pharmaceuticals, Inc. Dosage de copolymère
US20090029766A1 (en) * 2007-07-26 2009-01-29 Lutnick Howard W Amusement gaming access and authorization point
WO2009016643A1 (fr) * 2007-07-31 2009-02-05 Natco Pharma Limited Procédé de préparation de l'acétate de glatiramer (copolymère-1)
KR101751406B1 (ko) 2007-10-16 2017-06-27 펩팀문, 인코포레이티드 에피토프의 지정 확장에 의해 지정 서열 중합체 조성물을 포함하는 백신을 설계하고 제조하는 방법
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
EP2111105A4 (fr) * 2007-11-28 2011-05-04 Procédé pour retarder le début d'une sclérose en plaques cliniquement définie
WO2009129018A1 (fr) 2008-04-16 2009-10-22 Momenta Pharmaceuticals, Inc. Analyse de compositions copolymères d'acides aminés
JP2011530523A (ja) * 2008-08-07 2011-12-22 サイノファーム タイワン リミテッド 酢酸グラチラマーの合成
US8399600B2 (en) * 2008-08-07 2013-03-19 Sigma-Aldrich Co. Llc Preparation of low molecular weight polylysine and polyornithine in high yield
US9617313B2 (en) * 2008-12-24 2017-04-11 Synthon Bv Process for purifying a polymer mixture
ES2523732T5 (es) 2009-04-03 2023-10-23 Momenta Pharmaceuticals Inc Control de composiciones de copolímeros
EP2438080B1 (fr) 2009-06-04 2013-12-04 Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) Procédé de préparation de copolymère-1 (cop-1), composé à base de l-alanine, l-lysine, acide l-glutamique et l-tyrosine pour le traitement de la sclérose en plaques
RS52367B (en) * 2009-07-15 2012-12-31 Teva Pharmaceutical Industries Ltd. GLATIRAMER ACETATE FORMULATION FORMATED VOLUMES AND APPLICATION PROCEDURES
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US8691790B2 (en) * 2009-07-27 2014-04-08 James Layne Boucher Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
EA019998B9 (ru) 2009-08-20 2016-01-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. Терапия глатирамером ацетатом с низкой кратностью
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
EP3536333B1 (fr) 2010-01-04 2022-08-03 Mapi Pharma Limited Systeme de depot comprenant de l'acetate de glatiramer
WO2011086470A1 (fr) 2010-01-13 2011-07-21 Ramot At Tel-Aviv University Ltd Traitement de la sclérose en plaques
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
ES2694100T3 (es) 2010-04-07 2018-12-18 California Institute Of Technology Vehículo para distribuir un compuesto en una membrana mucosa y composiciones, procedimientos y sistemas relacionados
JP2013529194A (ja) * 2010-04-27 2013-07-18 ドクター レディズ ラボラトリーズ リミテッド ポリペプチドおよびその塩の調製
WO2011146910A1 (fr) 2010-05-20 2011-11-24 Round June L Treg spécifiques d'un antigène et compositions, procédés et systèmes associés
US9109006B2 (en) 2010-07-29 2015-08-18 Santhanakrishnan Srinivasan Glatiramer acetate molecular weight markers
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
WO2012123959A2 (fr) 2011-02-14 2012-09-20 Usv Limited Copolymère-1, son procédé de préparation et méthodes d'analyse de celui-ci
ES2601892T3 (es) * 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
WO2012150495A1 (fr) 2011-05-05 2012-11-08 National Institute Of Immunology Peptides synthétiques et copolymères aléatoires pour le traitement de troubles auto-immuns
WO2013009885A2 (fr) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation de diéthylamide de copolymère
WO2013009864A1 (fr) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Évaluation de structure de mélanges polypeptidiques hétérogènes
WO2013009945A1 (fr) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Compositions de psa contenant des lipides, procédés d'isolement et procédés pour les utiliser
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
CA2851510A1 (fr) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Polymorphismes de nucleotide simple utiles pour predire une reponse clinique a l'acetate de glatiramere
WO2013139728A1 (fr) 2012-03-19 2013-09-26 Synthon Bv Test d'activité biologique de l'acétate de glatiramère à base de cellules monocytaires humaines
EP2642290A1 (fr) 2012-03-19 2013-09-25 Synthon BV Analyse de la puissance de l'acétate de glatiramère basée sur des lignées de cellules monocytaires humaines
US20140045740A1 (en) * 2012-08-13 2014-02-13 Momenta Pharmaceuticals, Inc. Analysis of glatiramer acetate
CA2884267A1 (fr) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Marqueurs biologiques predictifs de la reponse clinique a l'acetate de glatiramer
WO2014060942A2 (fr) * 2012-10-20 2014-04-24 Mahesh Kandula Compositions et méthodes pour le traitement de la sclérose en plaques et de maladies neurodégénératives
WO2014128079A1 (fr) 2013-02-19 2014-08-28 Synthon B.V. Formulation multidose d'acétate de glatiramère
PL2774640T3 (pl) 2013-03-08 2015-04-30 Teva Pharma Wielorazowe urządzenie strzykawkowe dla strzykawki
RS53741B1 (en) 2013-03-08 2015-06-30 Teva Pharmaceutical Industries Ltd. Injectable Reusable Injection Device
CA2903805A1 (fr) 2013-03-14 2014-10-02 Mylan Inc. Essai de puissance d'acetate de glatiramere par biomarqueurs de reponse arnm
WO2014173463A1 (fr) 2013-04-26 2014-10-30 Synthon Bv Test d'activité biologique basé sur les lignées cellulaires monocytaires humaines au moyen d'acétate de glatiramère
EP2994161B1 (fr) 2013-05-10 2020-10-28 California Institute of Technology Prévention et traitement probiotiques du cancer du côlon
CN103265624B (zh) * 2013-05-27 2015-04-22 成都圣诺生物制药有限公司 格拉替雷的制备方法
CN104371012A (zh) * 2013-08-12 2015-02-25 深圳翰宇药业股份有限公司 一种合成醋酸格拉替雷的方法
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CA2928084A1 (fr) 2013-10-24 2015-04-30 Mylan Inc. Dosage de lignee de cellules t humaines pour evaluer l'identite immunologique de preparations d'acetate de glatiramere
WO2015101988A1 (fr) 2013-12-31 2015-07-09 Yeda Research And Development Co. Ltd. Diagnostic du lupus érythémateux systémique à l'aide d'oligonucléotides antigènes
AU2015228372B2 (en) 2014-03-12 2018-05-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
CN104844697B (zh) 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
WO2016139659A1 (fr) 2015-03-01 2016-09-09 Immunarray Ltd. Diagnostic du lupus érythémateux systémique à l'aide d'antigènes protéiques, peptidiques et oligonucléotidiques
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
WO2017031431A1 (fr) 2015-08-19 2017-02-23 President And Fellows Of Harvard College Compositions de psa lipidés et procédés associés
EP3147667B1 (fr) 2015-09-24 2019-06-12 CHEMI S.p.A. Analyse de la distribution du poids moléculaire de mélanges de polypeptides complexes
EP3170836B1 (fr) 2015-11-23 2018-10-24 Chemi SPA Analyse rp-hplc de mélanges de polypeptides complexes
CN107522774B (zh) * 2016-06-22 2021-07-02 深圳翰宇药业股份有限公司 一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
US20210220428A1 (en) 2016-06-30 2021-07-22 Stem Cell Medicine Ltd. Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
EP3484441A4 (fr) 2016-07-15 2020-03-18 President and Fellows of Harvard College Compositions de glycolipide et procédés d'utilisation
WO2018042423A1 (fr) 2016-08-28 2018-03-08 Mapi Pharma Ltd. Procédé pour préparer des microparticules contenant de l'acétate de glatiramère
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
RS64445B1 (sr) 2016-08-31 2023-09-29 Mapi Pharma Ltd Depo sistemi koji sadrži glatiramer acetat
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
US11510946B2 (en) 2017-05-15 2022-11-29 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
CN110709091A (zh) 2017-05-15 2020-01-17 干细胞医药有限公司 使用长效格拉替雷和脂肪源性干细胞治疗多发性硬化症
EP3765034A1 (fr) 2018-03-12 2021-01-20 Yeda Research and Development Co. Ltd Traitement d'une maladie cardiaque

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US4444760A (en) 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
JPS6053535A (ja) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
AR247097A1 (es) 1985-06-18 1994-11-30 Univ Emory Procedimiento para preparar composiciones farmaceuticas que incluyen copolimeros biologicamente activos como agente activo.
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
US4828706A (en) 1988-03-07 1989-05-09 Spectrum Medical Industries Process for performing a dialysis operation
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
DE8900366U1 (de) * 1989-01-13 1989-08-03 Indag Gesellschaft für Industriebedarf mbH, 69214 Eppelheim Folienbeutel
CA2009996A1 (fr) * 1989-02-17 1990-08-17 Kathleen S. Cook Procede de production de genes encodant des polymeres aleatoires d'acides amines
SU1690368A1 (ru) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
CN1073980A (zh) * 1991-11-12 1993-07-07 纳幕尔杜邦公司 胶原样多肽
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
EP0983020A1 (fr) 1997-05-06 2000-03-08 Quanta Vision, Inc. Appareil d'analyse de tissu
JP4328050B2 (ja) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
US6936539B2 (en) * 2003-09-24 2005-08-30 Micron Technology, Inc. Antireflective coating for use during the manufacture of a semiconductor device

Also Published As

Publication number Publication date
NZ287335A (en) 1999-02-25
CN1152874A (zh) 1997-06-25
FI964600A0 (fi) 1996-11-15
NO324528B1 (no) 2007-11-12
US6054430A (en) 2000-04-25
SK149396A3 (en) 1997-08-06
KR970703154A (ko) 1997-07-03
CZ341096A3 (en) 1997-06-11
NL300096I1 (nl) 2002-10-01
US5800808A (en) 1998-09-01
US8367605B2 (en) 2013-02-05
HU223473B1 (hu) 2004-07-28
ATE212857T1 (de) 2002-02-15
NO964976L (no) 1997-01-23
US20040106554A1 (en) 2004-06-03
JP3715600B2 (ja) 2005-11-09
ES2172586T3 (es) 2002-10-01
BR9507758A (pt) 1997-09-23
IL133890A0 (en) 2001-04-30
DE10299030I1 (de) 2003-01-23
EE03423B1 (et) 2001-06-15
WO1995031990A1 (fr) 1995-11-30
HUT75672A (en) 1997-05-28
NL300096I2 (nl) 2003-02-03
SI0762888T1 (en) 2002-08-31
US6342476B1 (en) 2002-01-29
PT762888E (pt) 2002-07-31
HK1008657A1 (en) 1999-05-14
PL317331A1 (en) 1997-04-01
JP2003105000A (ja) 2003-04-09
US20070117757A1 (en) 2007-05-24
TJ392B (en) 2004-10-13
CN1310673C (zh) 2007-04-18
MD1443F1 (en) 2000-04-30
EP0762888B1 (fr) 2002-02-06
DE69525340D1 (de) 2002-03-21
US7199098B2 (en) 2007-04-03
US6362161B1 (en) 2002-03-26
DE69525340T2 (de) 2002-09-19
NO964976D0 (no) 1996-11-22
US20050171286A1 (en) 2005-08-04
FI964600A (fi) 1996-12-05
JPH10500955A (ja) 1998-01-27
CN1626238A (zh) 2005-06-15
EP0762888A1 (fr) 1997-03-19
EP0762888A4 (fr) 1997-04-16
FI120236B (fi) 2009-08-14
US20120077754A1 (en) 2012-03-29
LU90987I2 (fr) 2003-02-25
GEP20002205B (en) 2000-08-25
HU9603243D0 (en) 1997-01-28
MD1443G2 (ro) 2000-11-30
US6620847B2 (en) 2003-09-16
US20030064914A1 (en) 2003-04-03
US6939539B2 (en) 2005-09-06
CA2191088A1 (fr) 1995-11-30
CA2191088C (fr) 2004-09-28
UA62908C2 (uk) 2004-01-15
CN1174753C (zh) 2004-11-10
PL181026B1 (pl) 2001-05-31
CZ292247B6 (cs) 2003-08-13
IL113812A0 (en) 1995-08-31
KR100403750B1 (ko) 2006-02-13
AU2602195A (en) 1995-12-18
US6048898A (en) 2000-04-11
IL113812A (en) 2000-06-29
US7625861B2 (en) 2009-12-01
US5981589A (en) 1999-11-09
BRPI9507758B1 (pt) 2021-03-16
EE9600170A (et) 1997-06-16
SK283699B6 (sk) 2003-12-02

Similar Documents

Publication Publication Date Title
DK0762888T3 (da) Copolymer-1 forbedringer i præparater af copolymerer
ES2120042T3 (es) Polimero de varilla rigida a base de piridobisimidazol.
DK0948357T3 (da) Anvendelse af aminoalkoholer med lav molekylevægt i oftalmiske sammensætninger
DK0728148T3 (da) Forbedrede immunogene sammensætninger mod humant gastrin 17
DE69633436D1 (de) Ethylen-copolymer-zusammensetzung
DE69113496D1 (de) Polymerzusammensetzungen.
ATE331037T1 (de) Isoliertes frpb nukleinsäuremolekül und entsprechende impfstoff
DE69406766D1 (de) Polyoxymetalate-Gruppen enthaltende Organosiloxan-Zusammensetzungen
ATE385805T1 (de) Neue peptide
SE9602822D0 (sv) New receptor
FI930265A0 (fi) Antikoagulantpeptider
BR9704377A (pt) Composições de borracha contendo n,n'-bis (hidroxifenil) maleamida
DE68914047D1 (de) Polymer-Zusammensetzungen.
BR9609114A (pt) Composição inseticida de terra diatomácea
DE59108093D1 (de) Spermicides Beschichtungsmittel
FR2656321B1 (fr) Compositions comprenant des copolymeres d'ethylene.
HUP9904128A2 (hu) Szappankészítmény
BR9914980A (pt) Composições para tratamento de tecido tendo reduzida abrasão do tecido